Archive | September, 2013

Biopharma Stocks Take Another Leg Up: ALXN, CBST, PCYC, REGN

Biotech Stocks Will Not Wait for Congress-Huge Rally Across the Board Analysts and Media are Piling On-Momentum Rules IBB up 1.75% XBI up 1.81% Rayno Biopharmaceuticals stocks are in a new leg up with large cap winners: Alexion (ALXN $115) up 2% Cubist (CBST $67.62)  up 2.95% Pharmacyclics (PCYC $130.59) up 9.73% Regeneron (REGN $305) […]

Continue Reading 0

Biotechnology IPO Market Continues Run with Foundation Medicine (FMI)

Foundation Medicine (FMI) Soars on IPO-Up 75% Foundation Medicine (FMI $32.30), based in Cambridge  MA, went public today at $18 offering 5,888,888 M shares and promptly went up 79% on volume over 4.5M shares as of early trading. See IPO Desktop for more information on the hot IPO market. (Careful the hot IPO of August Intrexon […]

Continue Reading 0

Fidelity Select Biotechnology Fund (FBIOX) Outperforms Biotech ETFs YTD

Life Science Sector at or Near YTD and All Time Highs Fidelity Fund (FBIOX) Outperform ETFs Over the past 3 years we reviewed how ETFs complement a biotechnology  investment strategy and compared three of the largest and most liquid : FBT, IBB and XBI (see the articles below and our comprehensive article from May 2011). […]

Continue Reading 0

Politics Curb Further Market Gains-Short Term Caution

No matter what your political persuasion you should know that your dysfunctional government may weaken the economy and damage your portfolio. Jim McTague in his Sep 23 Barron’s column, The GOP’s Threat to Investors, provides the scenario whereby he says…” Ben Bernanke never underestimates the ability of Congress to blow up the economy. Neither should […]

Continue Reading 0

Biotech Trading Notes: AEGR, ARRY, CLVS, REGN, RPRX- Update 1 Market Rallies Post FED

No Taper Rallies Stocks and Bonds-Equities up almost 1% Most sectors and stocks turned bright green after FED announces “No Taper”. Biotech stocks are up with IBB up 1%. Drug stocks very strong due to dividend plays and lower 10 year yield (2.724%). Gold up $34 with weak dollar. Oil up 2.63% on energy stocks […]

Continue Reading 0

Kythera (KYTH) Soars on Phase III Fat Drug Update 1

Chin-Up and Out! KYTH traded 2.58M shares today closing near its gap up 25% this morning at $41.95 . There was distribution of stock probably from early investors to funds and retail. The market cap is $774M. As of June 30,2013 reporting the Company had Shareholder equity of $45.8M and Cash of about $76M. Insiders […]

Continue Reading 0

Biotech Sector Hits New Highs On “FED Rally”: ALKS, ASTX, IBB, VPHM

“Yellen” Effect Boosts Markets-FED Policies Clarified With Larry Summers dropping out as a likely candidate for FED Chairman the market may be assured of a continuation of current FED policy. The market sees no surprises in Janet Yellen who is a frontrunner, as she is current Vice Chairman and has been a voting member of […]

Continue Reading 0

Mixed Tape in Biotech with Several Rayno Winners: ARRY, BIIB, ILMN, RGDX

NASDAQ Struggling As AAPL Down 5%–IBB ($205.36) off 0.4% Near All Time High of $207.78 The market is trying to continue its resilience since the hits on Syria were postponed pending Russian efforts with Assad. The 10 Year Treasury had an A+ offering at 2.94%.This is the highest auction yield since June’11. This is a […]

Continue Reading 0

Money Talks, Stocks Run, Don’t Walk and Biotech is Up 1.4% Update 1 ASTX up 23%

M&A Moves Down the Food Chain: Otsuka to Buy Astex for ~$900M Astex Pharmaceuticals (ASTX $8.22) has been on our focus list since 12/27/11 at $1.63 and today the stock is up 23% on buy-out news as Otsuka seeks cancer drug pipeline. Coming soon, a comparison of mid-cap biopharma stocks. Astex (ASTX) is the 7th Company […]

Continue Reading 0

Are Biotech M&A Premiums Already Built-In? Valuations Do Matter.

(Published this am in Seeking Alpha) Onyx Pharmaceuticals (ONXX) $10.4B Buy-Out Fuels Speculative Deal Lists We have written extensively on the life science bull market and its underpinnings: cheap money, scientific breakthroughs, sales growth and of course, M&A. The recent acquisition of Onyx Pharmaceuticals, Inc. by Amgen, Inc. has triggered analysis and commentary on the […]

Continue Reading 0